AU2001253020A1 - Screening markers and methods for neurodegenerative disorders - Google Patents

Screening markers and methods for neurodegenerative disorders

Info

Publication number
AU2001253020A1
AU2001253020A1 AU2001253020A AU5302001A AU2001253020A1 AU 2001253020 A1 AU2001253020 A1 AU 2001253020A1 AU 2001253020 A AU2001253020 A AU 2001253020A AU 5302001 A AU5302001 A AU 5302001A AU 2001253020 A1 AU2001253020 A1 AU 2001253020A1
Authority
AU
Australia
Prior art keywords
methods
neurodegenerative disorders
screening markers
markers
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253020A
Inventor
Frederique Bard
Kate D. Games
Tan Hua
Lisa C Mcconlogue
Elizabeth Messersmith
Theodore A Yednock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of AU2001253020A1 publication Critical patent/AU2001253020A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
AU2001253020A 2000-03-30 2001-03-30 Screening markers and methods for neurodegenerative disorders Abandoned AU2001253020A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19384700P 2000-03-30 2000-03-30
US60/193,847 2000-03-30
PCT/US2001/010247 WO2001075165A2 (en) 2000-03-30 2001-03-30 Screening markers and methods for neurodegenerative disorders

Publications (1)

Publication Number Publication Date
AU2001253020A1 true AU2001253020A1 (en) 2001-10-15

Family

ID=22715260

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253020A Abandoned AU2001253020A1 (en) 2000-03-30 2001-03-30 Screening markers and methods for neurodegenerative disorders

Country Status (3)

Country Link
US (2) US6664442B2 (en)
AU (1) AU2001253020A1 (en)
WO (1) WO2001075165A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253020A1 (en) * 2000-03-30 2001-10-15 Elan Pharmaceuticals, Inc. Screening markers and methods for neurodegenerative disorders
CA2446666A1 (en) 2001-05-09 2002-11-14 Biovision Ag Method for detecting progredient chronic dementia, and associated peptides and detection reagents
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20070087376A1 (en) * 2004-08-30 2007-04-19 Potashkin Judith A Splice variants of pre-mRNA transcripts as biomarkers in idiopathic neurodegenerative diseases
JP5475994B2 (en) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド Anti-Aβ globulomer antibody, antigen-binding portion thereof, corresponding hybridoma, nucleic acid, vector, host cell, method for producing said antibody, composition comprising said antibody, use of said antibody and method of using said antibody.
RS53270B2 (en) 2005-11-30 2018-05-31 Abbvie Deutschland Monoclonal antibodies against amyloid beta protein and uses thereof
NO345996B1 (en) 2005-12-12 2021-12-13 Ac Immune Sa A beta 1-42-specific monoclonal antibodies with therapeutic properties.
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RS53174B (en) 2007-10-05 2014-06-30 Genentech Inc. Use of anti-amyloid beta antibody in ocular diseases
DK2324360T3 (en) * 2008-08-11 2018-05-14 Banyan Biomarkers Inc BIOMARKET DETECTION METHOD AND ASSAY OF NEUROLOGICAL CONDITION
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
WO2018207910A1 (en) * 2017-05-12 2018-11-15 ハウスウェルネスフーズ株式会社 Anti-inflammatory composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211428B1 (en) 1994-09-01 2001-04-03 Merck & Co., Inc. Transgenic mouse expressing a familial form of human amyloid precursor protein
WO1996009857A1 (en) 1994-09-27 1996-04-04 Joseph Elie Tefaye Golfers head movement detector
CA2222174A1 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
AU2001253020A1 (en) * 2000-03-30 2001-10-15 Elan Pharmaceuticals, Inc. Screening markers and methods for neurodegenerative disorders

Also Published As

Publication number Publication date
US20040213739A1 (en) 2004-10-28
US20020147998A1 (en) 2002-10-10
US6664442B2 (en) 2003-12-16
WO2001075165A2 (en) 2001-10-11
WO2001075165A3 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
AU2001253020A1 (en) Screening markers and methods for neurodegenerative disorders
AU2001297524A1 (en) Fen endonucleases
EP1344576B8 (en) Inline sifter
AU2001233626A1 (en) Marker
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2002216774A1 (en) Eas marker
AU2001229592A1 (en) Vaccines against neurodegenerative disorders
AU2002355513A1 (en) Road stud
AU2002231295A1 (en) Developed seed and methods for making the same
AU7433900A (en) Screening methods
AU2002339707A1 (en) Genetic screening methods
AUPQ872300A0 (en) Compounds and methods
AU2002241758A1 (en) Drug screening system
AU1553101A (en) Screening method
AU2002312314A1 (en) Compositions and methods for preventing neural tube disorders
AU6429000A (en) Screening method
AU2310900A (en) Screening methods
AU2002348807A1 (en) Screening method which uses BNPI and DNPI
AU2002303007A1 (en) System for traffic signals and traffic passing at intersections
AU2872501A (en) Screening method
AU2001258641A1 (en) Thoroughfare marking removal
AU2002220868A1 (en) Screening method
AU2002355493A1 (en) Methods and markers for identifying activated synapses
AU2003303311A1 (en) Methods for selecting and screening for trasformants